With positive results from a Phase II proof of concept controlled human infection model study evaluating Neumifil under its belt, the Scottish biotech is preparing to put the drug through its paces in a chronic obstructive pulmonary disease trial next year.

Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.

A recent survey showed healthcare as among the sectors US companies were most concerned about amid the ongoing China-US tensions over Taiwan. But how do biotech firms on the island itself view the current situation? We spoke to the president of one amid Taiwan’s imminent reopening.

A recent survey showed healthcare as the sector US public companies were most concerned about (after semiconductors) amid the ongoing China-US tensions over Taiwan. But how do biotech firms in Taiwan itself view the current situation? Scrip spoke to the president of one of the most innovative and active companies in the sector, amid the island’s imminent reopening to the world after over two long years under pandemic restrictions.